Archive for March, 2010

Older Entries

Statins and Diabetes Mellitus: part 2

31, Mar 2010

HDL also seems to be more quickly hydrolyzed in patients with insulin resistance, leading to lower HDL levels. Statins can reduce LDL levels by 18% to 55% and triglycerides by 7% to 30%; they can also increase HDL levels by 5% to 15%.

Statins and Diabetes Mellitus

30, Mar 2010

The number of people living with diabetes mellitus in the U.S. has crossed the 20 million mark, with 1.5 million cases having been diagnosed in 2005 alone. Because nearly 65% of this population will suffer from heart disease or stroke, it is crucial for health care professionals to continually investigate the efficacy of current diabetes [...]

Pharmaceutical Approval Update: Arformoterol Tartrate Inhalation Solution (Brovana)

29, Mar 2010

Arformoterol Tartrate Inhalation Solution (Brovana)
Manufacturer: Sepracor, Inc., Marlborough, MA
Indication: Arformoterol solution is indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. COPD is a slowly progressive disease of the airways that is characterized by a gradual loss of lung function.

Pharmaceutical Approval Update: Travoprost Z Ophthalmic Sterile Solution 0.004% (Travatan Z)

28, Mar 2010

Manufacturer: Alcon Laboratories, Inc., Fort Worth, TX Indication: Travoprost Z is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are intolerant of, or insufficiently responsive to, other IOP-lowering medications.
Drug Class: This agent is a synthetic prostaglandin F2a (PGF2a) analogue. Its chemical name is isopropyl (Z)-7-[(1 [...]

Pharmaceutical Approval Update

27, Mar 2010

Posaconazole Oral Suspension (Noxafil)
Manufacturer: Schering-Plough Corporation, Kenil-worth, NJ
Indication: Posaconazole is indicated for the treatment of oropharyngeal candidiasis, including infections refractory to generic itraconazole (Sporonox drug, (PriCara) and/or fluconazole (Diflucan, Pfizer). Oral candidiasis is a fungal infection of the mouth and throat caused by the yeast Candida.

The Clinical Use of Tipranavir in HIV Infection: DRUG INTERACTIONS AND CONTRAINDICATIONS

26, Mar 2010

TPV is given with ritonavir to increase its therapeutic concentration, thereby inhibiting HIV replication.
In clinical studies, TPV was an inhibitor of CYP 1A2, CYP 2C9, CYP 2C19, and CYP 2D6, but the net effect in vivo is not known. When given with 200 mg of ritonavir, TPV is an inhibitor of CYP 3A4, and it [...]

The Clinical Use of Tipranavir in HIV Infection: CLINICAL TRIALS

25, Mar 2010

The FDA’s approval of TPV was based on two randomized, controlled, open-label, multicenter phase 3 clinical trials, RESIST-1 and RESIST-2 (Randomized Evaluation of Strategic Intervention in Multidrug-Resistant Patients with Tipranavir). The trials enrolled a combined 1,159 triple antiretroviral class-experienced patients with a history of at least two prior PI-based antiretroviral regimens, including one therapeutic failure [...]

Pages: 1 2 3 4 Next

Older Entries
top